SCHEMBL1099475

SCHEMBL1099475

O=S(=O)(c1ccccc1)N(Cc1ccc(F)c(F)c1)c1sc2ccccc2c1Cl

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 7/20 0.53
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PKM P14618 1/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
CXCR3 P49682 2/20 0.39
NPC1 O15118 1/20 0.36
PGR P06401 2/20 0.36
RORC P51449 1/20 0.35
NR3C1 P04150 1/20 0.35
NR1H2 P55055 1/20 0.35
HIF1A Q16665 1/20 0.35
EPAS1 Q99814 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098784 0.89 TRPM8 (0.68) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1098686 0.88 TRPM8 (0.48) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1098634 0.88 PKM (0.54) TRPM8MEN1KMT2APKMCNR1
SCHEMBL1097984 0.87 MEN1 (0.60) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1100138 0.87 TRPM8 (0.53) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1098782 0.87 TRPM8 (0.68) TRPM8MEN1KMT2AL3MBTL1CNR1
SCHEMBL1098091 0.87 TRPM8 (0.53) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1098152 0.85 TRPM8 (0.44) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1098617 0.85 TRPM8 (0.54) TRPM8MEN1KMT2AL3MBTL1PKM
SCHEMBL1097642 0.83 TRPM8 (0.56) TRPM8MEN1KMT2AL3MBTL1CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885MEN1 1640/4885KMT2A 1231/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885MEN1 1640/4885KMT2A 1231/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885MEN1 1640/4885KMT2A 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.